Answers are grounded in this paper and cite their sources.
Inflammatory bowel disease (IBD) is a chronic relapsing intestinal disorder, and current therapies remain limited by toxicity, loss of response, and inability to reverse the underlying pathological microenvironment. Natural plant polysaccharides (NPPs) have attracted increasing attention owing to their low toxicity, high biocompatibility, structural diversity, and intrinsic bioactivities. This review systematically consolidates and analyzes microenvironment‐responsive delivery systems tailored to the pathological microenvironment of IBD, with particular emphasis on the relationships between NPP structures and colonic delivery performance, focusing on molecular weight, branching architecture, glycosidic linkages, and functional groups. A “four‐dimensional remodeling” framework is proposed, encompassing barrier repair, microbiota reconstruction, immune homeostasis, and redox balance, which are interconnected as a closed‐loop regulatory network rather than isolated dimensions. The translational advantages of NPP‐based systems over synthetic polymeric carriers are further evaluated, including microbiota‐enzyme‐triggered release, metabolic friendliness, and the “carrier‐drug” duality. Moreover, artificial intelligence is catalyzing the transition from empirical screening toward data‐driven precision design by enabling structural encoding, functional prediction, and formulation optimization. These advances may accelerate the development of next‐generation green, intelligent, and personalized polysaccharide‐based therapeutics for the precision management of IBD.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: